Literature DB >> 33368923

Regulation of GluA1 phosphorylation by d-amphetamine and methylphenidate in the cerebellum.

Laura Cutando1, Emma Puighermanal1,2, Laia Castell1, Pauline Tarot1, Federica Bertaso1, Patricia Bonnavion3, Alban de Kerchove d'Exaerde3, Elsa Isingrini4,5, Micaela Galante6, Glenn Dallerac6, Vincent Pascoli7, Christian Lüscher7, Bruno Giros4,5, Emmanuel Valjent1.   

Abstract

Prescription stimulants, such as d-amphetamine or methylphenidate are used to treat suffering from attention-deficit hyperactivity disorder (ADHD). They potently release dopamine (DA) and norepinephrine (NE) and cause phosphorylation of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor subunit GluA1 in the striatum. Whether other brain regions are also affected remains elusive. Here, we demonstrate that d-amphetamine and methylphenidate increase phosphorylation at Ser845 (pS845-GluA1) in the membrane fraction of mouse cerebellum homogenate. We identify Bergmann glial cells as the source of pS845-GluA1 and demonstrate a requirement for intact NE release. Consequently, d-amphetamine-induced pS845-GluA1 was prevented by β1-adenoreceptor antagonist, whereas the blockade of DA D1 receptor had no effect. Together, these results indicate that NE regulates GluA1 phosphorylation in Bergmann glial cells in response to prescription stimulants.
© 2020 Society for the Study of Addiction.

Entities:  

Keywords:  Bergmann glial cells; GluA1; cerebellar cortex; monoaminergic system; prescription stimulants

Mesh:

Substances:

Year:  2020        PMID: 33368923     DOI: 10.1111/adb.12995

Source DB:  PubMed          Journal:  Addict Biol        ISSN: 1355-6215            Impact factor:   4.280


  1 in total

1.  Cerebellar dopamine D2 receptors regulate social behaviors.

Authors:  Laura Cutando; Emma Puighermanal; Laia Castell; Pauline Tarot; Morgane Belle; Federica Bertaso; Margarita Arango-Lievano; Fabrice Ango; Marcelo Rubinstein; Albert Quintana; Alain Chédotal; Manuel Mameli; Emmanuel Valjent
Journal:  Nat Neurosci       Date:  2022-06-16       Impact factor: 28.771

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.